154 related articles for article (PubMed ID: 37945610)
21. Elucidating Cuproptosis-Associated Genes in the Progression from Nash to HCC Using Bulk and Single-Cell RNA Sequencing Analyses and Experimental Validation.
Zhao Z; Luan T; Wan J; Du H; Hu J; Liu H; Gong X; Kuang G; Wang B
Medicina (Kaunas); 2023 Sep; 59(9):. PubMed ID: 37763758
[No Abstract] [Full Text] [Related]
22. Identification of hub genes and key pathways associated with the progression of gynecological cancer.
Zhang X; Wang Y
Oncol Lett; 2019 Dec; 18(6):6516-6524. PubMed ID: 31788113
[TBL] [Abstract][Full Text] [Related]
23. Ferredoxin 1 is a cuproptosis-key gene responsible for tumor immunity and drug sensitivity: A pan-cancer analysis.
Yang L; Zhang Y; Wang Y; Jiang P; Liu F; Feng N
Front Pharmacol; 2022; 13():938134. PubMed ID: 36210836
[TBL] [Abstract][Full Text] [Related]
24. Copper and cuproptosis-related genes in hepatocellular carcinoma: therapeutic biomarkers targeting tumor immune microenvironment and immune checkpoints.
Wang X; Chen D; Shi Y; Luo J; Zhang Y; Yuan X; Zhang C; Shu H; Yu W; Tian J
Front Immunol; 2023; 14():1123231. PubMed ID: 37153542
[TBL] [Abstract][Full Text] [Related]
25. Cuproptosis-related risk score predicts prognosis and characterizes the tumor microenvironment in colon adenocarcinoma.
Wang J; Tao Z; Wang B; Xie Y; Wang Y; Li B; Cao J; Qiao X; Qin D; Zhong S; Hu X
Front Oncol; 2023; 13():1152681. PubMed ID: 37333810
[TBL] [Abstract][Full Text] [Related]
26. High expression of cuproptosis-related gene FDX1 in relation to good prognosis and immune cells infiltration in colon adenocarcinoma (COAD).
Wang L; Cao Y; Guo W; Xu J
J Cancer Res Clin Oncol; 2023 Jan; 149(1):15-24. PubMed ID: 36173462
[TBL] [Abstract][Full Text] [Related]
27. Development and validation of cuproptosis molecular subtype-related signature for predicting immune prognostic characterization in gliomas.
Huang H; Lv Z; Yang L; Zhang X; Deng Y; Huang Z; Bi H; Sun X; Zhang M; Hu D; Liang H; Hu F
J Cancer Res Clin Oncol; 2023 Oct; 149(13):11499-11515. PubMed ID: 37392200
[TBL] [Abstract][Full Text] [Related]
28. A comprehensive analysis and experimental validation of TK1 in uterine corpus endometrial carcinoma.
Sun Y; Zhang K; Wang T; Zhao S; Gao C; Xue F; Wang Y
Sci Rep; 2024 Mar; 14(1):6134. PubMed ID: 38480789
[TBL] [Abstract][Full Text] [Related]
29. A Novel Cuproptosis-Related Prognostic Gene Signature and Validation of Differential Expression in Clear Cell Renal Cell Carcinoma.
Bian Z; Fan R; Xie L
Genes (Basel); 2022 May; 13(5):. PubMed ID: 35627236
[TBL] [Abstract][Full Text] [Related]
30. Characterization of cuproptosis identified immune microenvironment and prognosis in acute myeloid leukemia.
Luo D; Liu S; Luo J; Chen H; He Z; Gao Z; Wen Z; Liu X; Xu N
Clin Transl Oncol; 2023 Aug; 25(8):2393-2407. PubMed ID: 36826709
[TBL] [Abstract][Full Text] [Related]
31. FAT2 mutation is associated with better prognosis and responsiveness to immunotherapy in uterine corpus endometrial carcinoma.
Wang Z; Xing L; Huang Y; Han P
Cancer Med; 2023 Feb; 12(3):3797-3811. PubMed ID: 36812126
[TBL] [Abstract][Full Text] [Related]
32. RNA modification regulator DDC in endometrial cancer affects the tumor microenvironment and patient prognosis.
Zhao H; Shi C; Zhao G; Liu J; Wang X; Liang J; Li F
Sci Rep; 2023 Oct; 13(1):18057. PubMed ID: 37872211
[TBL] [Abstract][Full Text] [Related]
33. TIMM8A is associated with dysfunction of immune cell in BRCA and UCEC for predicting anti-PD-L1 therapy efficacy.
Zhu X; Yuan Z; Cheng S; Wang H; Liao Y; Zhou D; Wu Z
World J Surg Oncol; 2022 Oct; 20(1):336. PubMed ID: 36207751
[TBL] [Abstract][Full Text] [Related]
34. CXC chemokines: Potential biomarker and immunotherapeutic target for uterine corpus endometrial carcinoma.
Wang G; Fu J; Liu M; Zheng Q
PLoS One; 2024; 19(1):e0277872. PubMed ID: 38232115
[TBL] [Abstract][Full Text] [Related]
35. LAMP3 is a potent uterine corpus endometrial carcinoma prognostic biomarker associated with immune behavior.
Fu B; Zhou M; Geng X; Jiang Y; Zeng H; Zhou X; Yu Z; Pan J; Zhu Y; Zheng H; Huang S; Gong Y; Huang D; Zhong Y
Aging (Albany NY); 2024 Jan; 16(1):714-745. PubMed ID: 38217544
[TBL] [Abstract][Full Text] [Related]
36. Cuproptosis-related gene FDX1 as a prognostic biomarker for kidney renal clear cell carcinoma correlates with immune checkpoints and immune cell infiltration.
Yao Y; Chen H; Lou M; Chen T
Front Genet; 2023; 14():1071694. PubMed ID: 36755576
[No Abstract] [Full Text] [Related]
37. Regulation, genomics, and clinical characteristics of cuproptosis regulators in pan-cancer.
Zhou C; Li C; Zheng Y; Huang X
Front Oncol; 2022; 12():934076. PubMed ID: 36387247
[TBL] [Abstract][Full Text] [Related]
38. Prognostic analysis of cuproptosis-related gene in triple-negative breast cancer.
Sha S; Si L; Wu X; Chen Y; Xiong H; Xu Y; Liu W; Mei H; Wang T; Li M
Front Immunol; 2022; 13():922780. PubMed ID: 35979353
[TBL] [Abstract][Full Text] [Related]
39. Confirmation of the predictive function of cuproptosis-related gene FDX1 in clear cell renal carcinoma using qRT-PCR and western blotting.
Cai C; Zhou K; Jing J; Ren Y; Weng G; Cen D; Wang X; Huang S
Aging (Albany NY); 2023 Jul; 15(13):6117-6134. PubMed ID: 37432054
[TBL] [Abstract][Full Text] [Related]
40. Relationships of Cuproptosis-Related Genes With Clinical Outcomes and the Tumour Immune Microenvironment in Hepatocellular Carcinoma.
Chen X; Hu G; Xiong L; Xu Q
Pathol Oncol Res; 2022; 28():1610558. PubMed ID: 36213162
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]